How would you treat a patient with TNBC with a residual strongly PR+, ER- breast mass on mastectomy after neoadjuvant KEYNOTE 522 based chemoimmunotherapy?

I would treat such a patient the same way that I would any patient with residual TNBC after neoadjuvant chemotherapy and pembrolizumab, which depends to some extent upon the patient's stage at diagnosis and the extent of residual disease at surgery - in patients with residual disease after neoadjuva...

Assuming that the original tissue biopsy was accurate as triple negative tumor, this may be a scenario with heterogenous tumor biology where initial biopsy sampling did not catch PR positivity, and following neoadjuvant therapy PR positive tumor clones remained as dominant residual disease. I would ...